Table 1 Comparison of clinicopathological features of patients in MBC and TN-IDC
MBC N = 81 | TN-IDC N = 162 | P value | |
|---|---|---|---|
Age | 0.41 | ||
Mean age (year) | 51.07 ± 1.291 | 52.35 ± 0.876 | |
Age | 0.93 | ||
≤ 50 | 38(47%) | 75(46%) | |
> 50 | 43(53%) | 87(54%) | |
Menstrual state | 0.20 | ||
Premenopausal | 44(54%) | 74(46%) | |
Postmenopausal | 37(46%) | 88(54%) | |
Tumour size(cm) | 0.03 | ||
≤ 2 | 23(28%) | 74(46%) | |
> 2 | 50(62%) | 78(48%) | |
Unknown | 8(10%) | 10(6%) | |
T stage | 0.04 | ||
TX | 8(10%) | 10(6%) | |
T1 | 24(30%) | 73(45%) | |
T2 | 41(50%) | 65(40%) | |
T3 | 4(5%) | 6(4%) | |
T4 | 4(5%) | 8(5%) | |
LN status | 0.04 | ||
Negative | 60(74%) | 98(60%) | |
Positive | 21(26%) | 64(40%) | |
N stage | 0.03 | ||
N0 | 60(74%) | 98(60%) | |
N1 | 10(12%) | 30(19%) | |
N2 | 7(9%) | 14(9%) | |
N3 | 4(5%) | 20(12%) | |
Distant metastasis | 1.00 | ||
No | 79(98%) | 159(98%) | |
Yes | 2(2%) | 3(2%) | |
AJCC stage | 0.58 | ||
I | 20(25%) | 56(35%) | |
II | 43(53%) | 62(38%) | |
III | 10(13%) | 31(19%) | |
IV | 2(2%) | 3(2%) | |
Unknown | 6(7%) | 10(6%) | |
AJCC stage | 0.20 | ||
I+II | 63 | 118 | |
III | 10 | 31 | |
Subtype | – | ||
Triple negative | 68(84%) | 162 | |
HR( −) HER-2( +) | 7(9%) | 0 | |
HR( +) HER-2( −) | 6(7%) | 0 | |
Chemotherapy | 0.12 | ||
Yes | 72(89%) | 153(94%) | |
No | 9(11%) | 9(6%) | |
Chemotherapy modalities | 0.29 | ||
Postoperative chemotherapy | 55(76%) | 126(82%) | |
Preoperative chemotherapy | 17(24%) | 27(18%) | |
Radiotherapy | 0.38 | ||
Yes | 41(51%) | 70(43%) | |
No | 35(43%) | 85(53%) | |
Unknown | 5(6%) | 7(4%) | |
Endocrine therapy | – | ||
Yes | 5(6%) | 0(0) | |
No | 76(94%) | 162(100%) | |
Anthracycline therapy | 0.62 | ||
Yes | 64(89%) | 133(87%) | |
No | 6(8%) | 16(10%) | |
Unknown | 2(3%) | 4(3%) | |
Taxane therapy | 0.41 | ||
Yes | 64(89%) | 142(93%) | |
No | 6(8%) | 7(5%) | |
Unknown | 2(3%) | 4(2%) | |
Platinum therapy | 0.26 | ||
Yes | 9(13%) | 12(8%) | |
No | 61(85%) | 137(90%) | |
Unknown | 2(2%) | 4(2%) | |
Operation | 0.91 | ||
Mastectomy | 66(81%) | 133(82%) | |
BCS | 15(19%) | 29(18%) | |
Operation | 0.41 | ||
ALND | 42(52%) | 93(57%) | |
SLNB | 39(48%) | 69(43%) | |